UBS raised the firm’s price target on Pediatrix Medical (MD) to $23 from $16.50 and keeps a Neutral rating on the shares. Pricing growth drove a strong Q3, and UBS expects stable hospital administrative fees in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical Group: Strong Financial Performance and Strategic Improvements Justify Buy Rating
- Pediatrix Medical reports Q3 adjusted EPS 67c, consensus 47c
- Pediatrix Medical raises FY25 adjusted EBITDA view to $270M-$290M
- MD Earnings this Week: How Will it Perform?
- Pediatrix Medical price target raised to $17 from $16 at Truist